Merck Announces Positive Phase 2b Trial Results for Skin Disease Drug

Key Facts

1Merck announced positive Phase 2b trial results for tulisokibart, an experimental drug for hidradenitis suppurativa.

Merck & Co., Inc. announced positive Phase 2b trial results for tulisokibart, an experimental antibody drug for the treatment of hidradenitis suppurativa. Seeking Alpha reported that the therapy met its primary endpoints in the MK-7240-012 clinical study, positioning the candidate for advancement into late-stage development.

The successful mid-stage data allows the company to progress the drug into Phase 3 clinical trials to further strengthen its immunology pipeline. In the equity markets, MRK closed at $149.32 on September 29, 2026, having traded between a session high of $150.36 and a low of $146.09.